← All trials
NCT05780086
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Feb 3, 2023
- Primary completion
- Aug 30, 2023
- Completion date
- Dec 30, 2023
- First posted
- Mar 22, 2023
- Last posted
- Mar 28, 2023
- Enrollment
- 10
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Instituto Mexicano del Seguro SocialLead sponsor
- Instituto Mexicano del Seguro SocialReponsible party - principal investigator
- Sequana Medical AGCollaborator
- Instituto Mexicano del Seguro SocialSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.